28.43
6.48%
-1.97
After Hours:
28.43
Immunovant Inc stock is currently priced at $28.43, with a 24-hour trading volume of 1.79M.
It has seen a -6.48% decreased in the last 24 hours and a -6.88% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $30.36 pivot point. If it approaches the $28.52 support level, significant changes may occur.
Immunovant Inc Stock (IMVT) Financials Data
Immunovant Inc (IMVT) Net Income 2024
IMVT net income (TTM) was -$243.45 million for the quarter ending December 31, 2023, a -22.52% decrease year-over-year.
Immunovant Inc (IMVT) Cash Flow 2024
IMVT recorded a free cash flow (TTM) of -$210.56 million for the quarter ending December 31, 2023, a -27.11% decrease year-over-year.
Immunovant Inc (IMVT) Earnings per Share 2024
IMVT earnings per share (TTM) was -$1.84 for the quarter ending December 31, 2023, a -10.84% decline year-over-year.
Immunovant Inc Stock (IMVT) Latest News
What Makes Immunovant (IMVT) a New Buy Stock
Zacks Investment Research
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
Zacks Investment Research
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
Zacks Investment Research
Immunovant Awarded U.S. Patent for IMVT-1402
GlobeNewswire Inc.
Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks
Zacks Investment Research
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
Zacks Investment Research
About Immunovant Inc
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Cap:
|
Volume (24h):